top of page
Our Portfolio
Our portfolio reflects the scale and diversity of the broader healthcare venture capital market.
For over 13 years, we have created customized solutions for venture funds, corporate venture funds, limited partnership interests, operating companies, and individual shareholders.
QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. It was acquired by Shionogi Pharma Inc. in 2017.

Aerpio Pharmaceuticals focuses on leveraging Tie2 activation for ocular disease and vascular stabilization. IPO in 2018 (NASDAQ: ARPO).

Esperion Therapeutics
focuses on the development of bempedoic acid. IPO in 2013 (NASDAQ: ESPR).

AcelRx Pharmaceuticals focuses on the development and commercialization of innovative therapies. IPO in 2011 (NASDAQ: ACRX).
bottom of page